Enovis (ENOV) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Enovis (ENOV) over the past year, losing 8.1% versus a loss of 43.6%. Over five years, TLSI leads with a -59.0% price change compared with -79.7% for ENOV. Enovis is the larger company by market cap ($1.02 billion vs $250.0 million), about 4.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | TLSI |
|---|---|---|
| Share price | $17.69 | $4.06 |
| Market cap | $1.02B | $249.99M |
| 1-day change | +1.49% | -1.69% |
| YTD return | -33.60% | -41.83% |
| 1-year return | -43.61% | -8.14% |
| 5-year return | -79.70% | -58.99% |
| Forward P/E | 4.93 | — |
| EPS (TTM) | $-19.23 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.25B | — |
| Revenue growth (YoY) | +6.66% | — |
| Net income (latest FY) | $-1.18B | — |
| Gross margin | 59.84% | — |
| Operating margin | -50.01% | — |
| Net margin | -52.69% | — |
| 52-week high | $34.28 | $7.95 |
| 52-week low | $16.70 | $2.20 |
| Distance from 52-week high | -48.40% | -48.93% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +112.44% | +156.16% |
| Average volume | 1.46M | 274.82K |
| Shares outstanding | 57.67M | 61.57M |
| Employees | 7,802 | 102 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Enovis is about 4.1 times larger than TriSalus Life Sciences by market value ($1.02B vs $249.99M).
- TLSI has outperformed ENOV by 35.5 percentage points over the past year.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
ENOV vs TLSI FAQ
Which is bigger, Enovis or TriSalus Life Sciences?
Enovis (ENOV) is larger, with a market capitalization of $1.02B compared with $249.99M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, ENOV or TLSI?
TLSI returned -8.14% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Enovis and Medical Specialities for TriSalus Life Sciences.